In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway

被引:24
作者
Kedia, Giorgi
Uckert, Stefan
Scheller, Friedemann
Chigogidze, Teimuraz
Managadze, Lauri
Jonas, Udo
Truss, Michael C.
机构
[1] Hannover Med Sch, Dept Urol, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Nucl Med, D-30625 Hannover, Germany
[3] Natl Ctr Urol, Tbilisi, Georgia
[4] Klinikzentrum Nord, Klinikum Dortmund, Dept Urol, Dortmund, Germany
关键词
D O I
10.1016/j.urology.2005.12.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To examine the effects of some nitric oxide-donating agents, as well as the C-type natriuretic peptide (CNP), on isolated human prostatic tissue. To date, guanylyl cyclases and cyclic guanosine monophosphate (cGMP)-degrading phosphodiesterases represent important target proteins for the development of new drugs for the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. Methods. Using the organ bath technique, the effects of sodium nitroprusside, S-nitrosoglutathione, S-nitrosocysteine, linsidomine, and CNP (1 nM to 1.0/10 mu M) on the tension induced by norepinephrine of prostatic tissue strips were investigated. The tissue was also exposed to three different concentrations of the drugs, and the production of cGMP and cyclic adenosine monophosphate (cAMP) was determined. Results. The tension induced by 40 mu M norepinephrine of the isolated prostatic tissue was dose dependently reversed by the drugs. The rank order of potency was sodium nitroprusside more than S-nitrosoglutathione more than linsidomine more than S-nitrosocysteine, which was equal to CNP (1 mu M). The reversal of tension induced by the greatest drug concentrations ranged from 50% relaxation with sodium nitroprusside to 42% relaxation with CNP. The relaxing effects of the drugs were paralleled by a 2-fold to 40-fold and 2-fold to 45-fold increase in tissue levels of cAMP and cGMP, respectively. Conclusions. Our results provide further evidence that cGMP and cAMP are involved in the control of the normal function of human prostatic smooth muscle. Our findings may provide new strategies for future therapeutics used in the treatment of lower urinary tract symptoms and bladder outlet obstruction secondary to benign prostatic hyperplasia.
引用
收藏
页码:1292 / 1297
页数:6
相关论文
共 28 条
  • [1] Aikawa K, 2001, PROSTATE, V48, P40
  • [2] S-nitrosothiols:: a class of nitric oxide-donor drugs
    Al-Sa'doni, H
    Ferro, A
    [J]. CLINICAL SCIENCE, 2000, 98 (05) : 507 - 520
  • [3] ANDERSON KE, 1993, PHARMACOL REV, V45, P253
  • [4] ANDERSSON KE, 1994, WORLD J UROL, V12, P249
  • [5] Future drugs for the treatment of benign prostatic hyperplasia
    Andersson, KE
    Chapple, CR
    Höfner, K
    [J]. WORLD JOURNAL OF UROLOGY, 2002, 19 (06) : 436 - 442
  • [6] Bloch W, 1997, PROSTATE, V33, P1
  • [7] CHARACTERIZATION AND LOCALIZATION OF NITRIC-OXIDE SYNTHASE IN THE HUMAN PROSTATE
    BURNETT, AL
    MAGUIRE, MP
    CHAMNESS, SL
    RICKER, DD
    TAKEDA, M
    LEPOR, H
    CHANG, TSK
    [J]. UROLOGY, 1995, 45 (03) : 435 - 439
  • [8] ADRENERGIC AND CHOLINERGIC RECEPTORS IN HUMAN PROSTATE, PROSTATIC CAPSULE AND BLADDER NECK
    CAINE, M
    RAZ, S
    ZEIGLER, M
    [J]. BRITISH JOURNAL OF UROLOGY, 1975, 47 (02): : 193 - 202
  • [9] DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691
  • [10] Denis L, 1998, PROSTATE, V37, P246, DOI 10.1002/(SICI)1097-0045(19981201)37:4<246::AID-PROS6>3.0.CO